Psoriasis Arthritis, SAPHO Syndrome, Sleep Apnea Syndromes
Conditions
Brief summary
Chronic inflammatory rheumatisms (CIR) are a source of motor disability and various comorbidities, particularly cardiovascular and metabolic. They also significantly impact patients' quality of life, including sleep disturbances. Among CIRs, psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis, typically seronegative for rheumatoid factor. This heterogeneous disease affects peripheral and/or axial joints and can include extra-articular manifestations such as uveitis and chronic inflammatory bowel diseases. Its prevalence is estimated between 0.3% and 1% in the general population. SAPHO syndrome, similar to psoriatic arthritis, is characterized by specific bone involvement with a hypertrophic tendency, often affecting the axial skeleton and the anterior thoracic wall. Pain and inflammation are closely linked to sleep quality, creating a vicious cycle where pain disrupts sleep and poor sleep amplifies pain perception. Analgesic treatments, such as opioids, can also cause nocturnal respiratory pathologies, further disrupting sleep. Inflammatory processes are regulated by sleep, influencing plasma concentrations of CRP, IL6, and TNF production. Patients with psoriatic arthritis or SAPHO syndrome share common risk factors with Obstructive Sleep Apnea Syndrome (OSAS), such as obesity, hypertension, and metabolic syndrome. Sleep disorders are common in the general population and likely underdiagnosed in these patients. Several studies suggest a link between sleep disorders and these rheumatic conditions, affecting quality of life and exacerbating symptoms. Questionnaires like the Epworth and Pichot scales provide a more precise evaluation of these symptoms. However, objective sleep exploration through polysomnography has never been conducted in these patients. In summary, CIRs, particularly psoriatic arthritis and SAPHO syndrome, significantly impact patients' quality of life and sleep, necessitating appropriate evaluation and management of associated sleep disorders.
Interventions
None listed
Sponsors
Fondation Hôpital Saint-Joseph
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient aged 18 years or older * Patient diagnosed with psoriatic arthritis or SAPHO syndrome and followed at Paris Saint-Joseph Hospital * Patient presenting sleep disorders warranting hospitalization for further -investigation of these disorders * French-speaking patient * Patient who does not oppose participation in the research protocol
Exclusion criteria
* Patient already followed for a sleep disorder * Patient who underwent polysomnography in the last 2 years * End-of-life patient * Patient under guardianship or curatorship * Patient deprived of liberty * Patient under legal protection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Type of sleep disorders | at 6months | sleep disorders will be defined after polysomnography exam. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| presence and severity of asthenia, | at enrollement | mesured by the PICHOT questionnar |
| evaluation of anxiety | at enrollement | mesured by HAD questionnaire |
| drowsiness evaluation | at enrollement | mesured with the Epworth Scale |
| sleep structure | at 6 months | quantity of the different sleep stages as observed on the polysomnography exam |
| Sleep apnea severy | at enrollemnt, 6months and 12 months after | mesured by the Apnea/hypopnea index |
| Rheumatism disease activity | at enrollement, after 6 months and after 12 months | mesured with the DPASA score |
| CRP mesurement | at enrollment, 6months and 12 months after | expressed in mg/L |
| Evaluation of Sleep Apnea | at enrollement, at 6months and at 12 months | mesured with the STOP BANG questionnaire |
Countries
France
Contacts
Primary ContactJuliette COURTIADE MAHLER
Outcome results
None listed